- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00830297
Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia (TIP)
Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia (TIP): Efficacy and Safety of a Novel Protocol in Renal Transplant Recipients Receiving a Tacrolimus-based Immunosuppression
Treat-to-target trial of basal Insulin in Post-transplant hyperglycemia (TIP): efficacy and safety of a novel protocol in renal transplant recipients receiving a tacrolimus-based immunosuppression
DESCRIPTION:
A prospective, randomized safety and efficacy study of long-acting insulin (Insulatard®) as therapy against post-transplant hyperglycemia in renal transplant recipients
OBJECTIVES:
Primary Objective:
To demonstrate superiority of long-acting insulin (Insulatard®) against post-transplant hyperglycemia, in comparison to conventional treatment, and as evaluated by HbA1c
Secondary Objectives:
- To assess the average post-transplant glucose levels in renal transplant patients under conventional blood-glucose lowering therapy during a period of at least 14 days after transplantation by measuring the capillary blood glucose levels four times daily in both groups of patients (fasting, before lunch, before supper, after supper)
- To detect the number of post-transplant patients who - without any history of pre-transplant diabetes - develop at least one episode of post-transplant hyperglycemia (> 140 mg/dl before supper)
- To detect the average number of hyperglycemic episodes in post-transplant patients with at least one episode of post-transplant hyperglycemia and without any history of diabetes
- To assess the amount of (long-acting) insulin (in IU) needed in order to obtain a target capillary blood glucose level in the range of 110 mg/dl to 120 mg/dl before supper in post-transplant patients with incidence of hyperglycemia
- To assess the safety of long-acting insulin in controlling post-transplant hyperglycemia (especially with regards to episodes of hypoglycemia (glucose-level < 60 mg/dl)
- To assess the prevalence of post-transplant diabetes, as diagnosed by an abnormal oral glucose tolerance on days 90, 180 and 360 after transplantation, in the group of patients which has been treated with long-acting insulin, in comparison to patients who received conventional treatment
- To assess the morbidity (hospitalization, infections, subsequent episodes of surgery, requirement of non-immunosuppressive, non- blood glucose lowering medication) in the group of patients with long-acting insulin for hyperglycemia, in comparison to patients randomized into the group receiving conventional treatment
- To assess the renal outcome (creatinine levels, rejections) in the group of patients which is foreseen to be treated with long-acting insulin for hyperglycemia, in comparison to patients randomized into the group receiving conventional treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
DESIGN / PHASE:
Prospective, single-center, randomized, parallel group, controlled, phase II study.
STUDY PLANNED DURATION:
First patient First visit 1Q 2009 Last patient First visit 4Q 2009 Last patient Last visit 4Q 2010
CENTERS:
Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria, Department of Surgery, Division of Transplantation, Medical University of Vienna, Austria
PATIENTS / GROUPS:
50 patients in 2 groups 25 patients per group Randomization ratio 1:1, no stratification
Capillary blood glucose will be measured four times daily: before breakfast (7:30 am), before lunch (12 pm), before supper (5:30 pm) and after supper (9 pm) in both groups by the nursing personnel/academic investigators. In group No.1 (study arm A), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
In group No.2 (study arm B), the glucose levels will be recorded, but the treatment will be left up to the ward, which is relying on conventional morning glucose measurements. For safety, any glucose levels >180 mg/dl will be reported, and all measures taken by the ward will be recorded. As there are no available guidelines however concerning the so called "conventional" blood glucose-lowering therapy in renal transplant patients, especially during this very early post-transplant phase, the following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than three times daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
EFFICACY ENDPOINTS:
Primary:
- HbA1c levels
Secondary:
- capillary blood glucose profile in patients treated with long-acting insulin and in the control group, as evaluated by the daily measurements
- number of patients and overall number of days with hyperglycemia > 140 mg/dl (in each group)
- number of patients and overall number of days with hyperglycemia > 200 mg/dl (in each group)
- number of patients and overall number of days with hypoglycemia < 60 mg/dl in each group
- number of patients with abnormal glucose tolerance on days 90, 180 and 360 after transplantation
TOLERABILITY / SAFETY ENDPOINTS:
- Number of incidences of symptomatic hypoglycemia, confirmed by capillary blood glucose levels < 60 mg/dl
PHARMACOKINETIC / PHARMACODYNAMIC ENDPOINTS:
Doses of (long-acting) insulin
STATISTICAL METHODOLOGY:
Primary Endpoint:
HbA1c (rel %)
Null and alternative hypotheses:
H0 Treatment of hyperglycemia > 140 mg/dl before supper with long-acting insulin in renal transplant recipients for a period of at least 14 days after transplantation is equal to conventional treatment in reducing the HbA1c (measured on day 90 after transplantation).
H1: Treatment of hyperglycemia > 140 mg/dl before supper with long-acting insulin in renal transplant recipients for a period of at least 14 days after transplantation is superior to conventional treatment in reducing the HbA1c (measured on day 90 after transplantation).
Type-I and -II errors - power:
α=0.05 ß=0.2
Statistical methodology:
One-sided t-test of HbA1c on day 90 after transplantation, one-sided t-test of number of days with hyperglycemia > 140 mg/dl before supper, comparison of capillary blood glucose levels by ANOVA
Sample size calculation:
Based on a two-sided testing and an expected standard deviation of HbA1c of 10%, an α=0.05 and a ß=0.2, a sample size of 25 patients per group was determined.
Main analysis set:
Per-protocol (efficacy) and intention to treat (ITT) for safety
Other endpoints:
descriptive statistics
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna, Department of Internal Medicine III
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- renal transplantation (deceased or living donor)
- eligibility for the standard immunosuppression of our center, consisting of tacrolimus, mycophenolate mofetil or mycophenolic acid, dexamethasone/prednisone triple therapy
- informed consent of the patient
Exclusion Criteria:
- patients with type 1 or type 2 diabetes
- allergy against long-acting insulin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1 Insulatard (long-acting insulin)
|
In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl.
The normoglycemic goal in this group will be from 110 to 120 mg/dl.
|
Active Comparator: 2 Conventional treatment
|
In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward.
The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl.
2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e.
Gliclazide - Diamicron®, 30 mg, not more than twice daily).
3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint is the difference in HbA1c between the two study arms.
Time Frame: post-transplant day 90
|
post-transplant day 90
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Capillary blood glucose profiles in each group
Time Frame: post-transplant day 1-21
|
post-transplant day 1-21
|
Number of patients and overall number of days with hyperglycemia >140 mg/dl before supper (in each group)
Time Frame: post-transplant day 1 - 21
|
post-transplant day 1 - 21
|
Number of patients and overall number of days with hyperglycemia >200 mg/dl (in each group)
Time Frame: post-transplant day 1-21
|
post-transplant day 1-21
|
Number of patients and overall number of days with hypoglycemia <60 mg/dl in each group
Time Frame: post-transplant day 1-21
|
post-transplant day 1-21
|
Number of patients with abnormal glucose tolerance
Time Frame: post-transplant day 90, 180 and 360
|
post-transplant day 90, 180 and 360
|
Difference in HbA1c between the two study arms
Time Frame: post-transplant day 180 and 360
|
post-transplant day 180 and 360
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Wilfred Druml, MD, Medical University of Vienna
Publications and helpful links
General Publications
- Lo C, Toyama T, Oshima M, Jun M, Chin KL, Hawley CM, Zoungas S. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Cochrane Database Syst Rev. 2020 Jul 30;8(8):CD009966. doi: 10.1002/14651858.CD009966.pub3.
- Davidson JA, Wilkinson A; International Expert Panel on New-Onset Diabetes after Transplantation. New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view. Diabetes Care. 2004 Mar;27(3):805-12. doi: 10.2337/diacare.27.3.805. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EudraCT: 2008-005951-84
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperglycemia
-
Mayo ClinicCompletedHospital Hyperglycemia | Post-transplant HyperglycemiaUnited States
-
Zealand University HospitalNot yet recruitingStress Hyperglycemia | Postoperative Hyperglycemia
-
University of CopenhagenUnknownSurgery--Complications | Hyperglycemia Stress | Hyperglycemia Steroid-inducedDenmark
-
University of LeedsCompletedEffect of Food on Postprandial HyperglycemiaUnited Kingdom
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...RecruitingHyperglycemia StressUnited States
-
Loughborough UniversityUniversity of BedfordshireCompletedPostprandial HyperglycemiaUnited Kingdom
-
Centre Hospitalier Universitaire de BesanconEli Lilly and Company; AstraZenecaCompleted
-
Medical University of ViennaCompleted
-
Addis Ababa UniversityCompletedHyperglycemia, Postprandial
-
University of Eastern FinlandFinnsugar LtdCompletedHyperglycemia, PostprandialFinland
Clinical Trials on Insulatard (long-acting insulin)
-
Emory UniversityCompletedDiabetes Mellitus | Type 1 DiabetesUnited States
-
Ain Shams UniversityCompletedLong Acting Insulin in Control of Gestational Diabetes MellitusEgypt
-
Slotervaart HospitalCompletedHyperglycemia Steroid-inducedNetherlands
-
US Department of Veterans AffairsCompletedHyperglycemia | DiabetesUnited States
-
LMC Diabetes & Endocrinology Ltd.SanofiCompletedType 2 Diabetes MellitusCanada
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Institut de Recherches Cliniques de MontrealNovo Nordisk A/S; McMaster UniversityCompleted
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1United States, Germany
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesAustria
-
Novo Nordisk A/SCompleted